MS and Demyelinating Disorders

Here's some of what is coming soon to NeurologyLive® this week.

The director of the Buffalo Neuroimaging Analysis Center talked about the ENLIGHTEN trial, where results showed a correlation between cognitive impairment and brain volume with ozanimod. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

Findings from data on patients with various autoimmune disorders who used remibrutinib, a BTK inhibitor in development for multiple sclerosis, reported no safety concerns in laboratory analyses.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 7, 2023.

The senior vice president for Research and Training at Kessler Foundation talked about the issue of fatigue in patients with multiple sclerosis and the significant, multifaceted challenges patients face. [WATCH TIME: 5 minutes]

Over a 96-week period, more older patients with relapsing multiple sclerosis on diroximel fumarate achieved no evidence of disease activity-3 status vs younger patients.

In the phase 3 OPTIMUM study of ponesimod, findings showed that MRI features in patients with multiple sclerosis were significantly associated with clinical scales.

The assistant professor at Hunter College discussed the approach of systematically localizing symptoms in patients with multiple sclerosis for diagnosis based on a clinical workshop. [WATCH TIME: 5 minutes]

The assistant professor at the University of Alabama at Birmingham discussed the transition from pediatric to adult care for patients with multiple sclerosis as well as the challenges presented in diagnosis, treatment, and understanding the long-term impact of the disease. [WATCH TIME: 5 minutes]

METEOROID is the first study to evaluate the efficacy and safety of satralizumab, an FDA-approved therapy for NMOSD, in patients with MOGAD.

Amy Perrin Ross, APN, Patricia Melville, NP-C, and Aliza Ben-Zacharia, PhD, DNP, ANP-BC discuss importance of evaluating immunogenicity of biosimilars.

Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss approval process of biosimilars.

A panel of experts in the treatment of patients with NMOSD discusses and offers insight into the vital aspects of diagnosis, disease management, and therapeutic strategy.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 30, 2023.

The head of the MS Center at Methodist Hospitals and assistant professor of neurology at Indiana University talked about the significance of diversity and the health disparities faced by patients with multiple sclerosis in the LGBTQ+ community. [WATCH TIME: 3 minutes]

Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.

A group of experts in the care of patients with neurological conditions—Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath; Andrew Solomon, MD; Anne H. Cross, MD; Anthony Feinstein, MPhil, PhD, FRCP; Brian G. Weinshenker, MD, FRCP—shared their perspectives on hot topics of treatment and management in multiple sclerosis from the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting.

John DeLuca, PhD, senior vice president for Research and Training at Kessler Foundation, discussed the challenges in understanding and measuring fatigue in patients with multiple sclerosis.

As a recap from CMSC 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

Clinical experts discuss differences and similarities between biosimilars and reference products.

Four advanced practice providers discuss biosimilars and how they can play an important role in healthcare.

In addition to increased relapse rates, use of fingolimod was associated with a 49% higher risk for disability accumulation in comparison with ocrelizumab.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

High and low doses of frexalimab resulted in reductions of new or enlarging T2 lesions and total T1 gadolinium-enhancing lesions over a 3-month period.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 23, 2023.

Dr Krieger, Dr Brandstadter, and Dr Lublin discuss the advances made in recognizing and managing multiple sclerosis over the last few decades and the challenges that remain.